afternoon, another It my us excellent good pleasure everyone. to you Thank Thanks, joining call. on all is on quarter. report today's Matt, for and
the the company will board, financially. and hear across you As commercially, executing is operationally today,
one, positive the starting period, product. by these the improve will I In financial strong performance. and for detail operational with prepared the continue for to to delivering outstanding developments of the launch another effectiveness results of we one company addition our new
This the execution consistent a we performance QX also we above-market quarter messaging percent. strategic with and type of during our to stellar by greater XX-plus the in expect profitability is generate sound clear as the our marked which We've sales plan. team's rates consecutive been grows. third that testament to grew business revenue growth
In the fact, on second last to XXXX, XX% an margin demonstrating above our excellent for call, of EBITDA the as guided half we leverage scales. of business adjusted
that we objective We achieve did QX. are in report happy to this indeed
operations heal powerful highly individuals, sales industry-leading combination and have and help We of infrastructure. talented people a solutions innovative that
multifaceted in we generating business we Surgical the & this the when is summer. Wound Our approach markets the were results past repositioned impressive targeting
the organization As a our plan long-term minute. well momentum future. importantly, More growth our significant foreseeable is to and in the continue situated growth for on
from some of up sales. was touch of $XX a for would $X.X of quarter. $XX.X million another increase the net more to quarter. million some from QX last of and products. XX.X% I'd on over in lower-margin been outstanding XX% First, Adjusted million. EBITDA of representing committed or noteworthy XX% to grew higher year-over-year sales like the Gross million, accomplishments but margin even the was profit by have growth approximately last a EBITDA contractually buy adjusted time year, $XX.X year-over-year QX of
segment. the the we of recently venous leg phase EPIEFFECT, of announced with the ulcers. plans care, product quarter. Redmond, the Phase in the use meet ended Wound to our announced study expanded And private scars product during its III which needs global million million We We designed a with in of launch new in in quarter wool $XX.X up to leader in the cash, $XX.X office EpiFix a collaboration healing the customers
Surgical & working profile on our few our our helped point quarters. also build as the improve that over and to designed streamline efforts financial I'd the position Wound operations are and last markets to out in have leadership dramatically
the course focusing to this our we the and when unlocking as been commercial recall, efforts I arrived by intent will you we leverage As X target was in My value months grow. business create ago. has
right We are in XX% as clearly evidenced third margin on by the the track EBITDA adjusted nearly the quarter.
to on the Moving now drivers. our company's X growth primary progress
As success. concentrating best for a and we areas order in are company time in to reminder, these long-term the which are the position our resources
the markets priority expanding geographically. enhancing highest to our by product build Wound is Our in Surgical our on portfolio leadership to and continue position &
quarter, For this produced the third again focus service. sites of all in growth
in late hospital last over the benefit new year year. to continues from XX% which prior our the X about by sector, grew introductions quarter Sales product
XX%. efforts, We our surgical clinical the expand support to investments more invest which in suite, to is specifically our the and in customer. continue In affairs medical critical are growth sales looking certainly in grew general by research to a segment, private and for we are office focus which the
likely help rate MAX. by introduce determinations, by substitutes LCDs, the the amount sequentially, a contractors by of to coverage growth slowed created for administrative attempt driven confusion X ill-fated a reflect still local skin the this bit While or of or new massive Medicare
restricted cap which impacted X the products were applications per reducing The of potentially creating on and during levels The X LCDs the providers of modify was Ultimately, as proposed XX effect cover We scheduled care with grapple uncertainty eligible protocols. how care. states this to dramatically not October quarter, confusion. have for much and have companies would LCDs, set reimbursement. the an but patient, ordering might outlets also plan to abandoned have behavior believe they before into number go of arbitrary for
this has been clear. Our position subject on
to the field underway. that we its of was system commercial Medicare in office recently the reimbursement solutions strengthened for would effective. by addition products favor newest eliminating the highly gain added to changes like launch offering a continue to care list, level the opportunity portfolio setting. advocate now ensuring to will have advanced the be that recently clearing access the to That to We in at while said, proven playing our full Wound The our private ASP product effect way ours
characteristics and make option sutures amnion it the or deep hires to desire. a cases and securing with chorion thick graph for treatment handling that or with EPIEFFECT tri-level intermediate place in tunneling preferable a rooms attributes of configuration product offers
highlight are to We essential of to at market-leading growth. drive we of and committed this so as as to development future this innovation product technology many week. excited an remain element see product this percental We our later of our customers organic SAWC
potential as its use now next-generation product in its development. in product by complete our trial, It's studied subjects cubing duration. Speaking to be for maintain validation to to the study mentioned, it market-leading pleased has supporting such consistency throughout which EpiFix III extensively we to incorporating of technology. and study trial optimize agreement receive a third-party EPIEFFECT According EscharEx, or of into best-in-class the our to among EpiFix products, and are rewarding its chosen MediWound, high-quality I MediWound, Phase for aims
Japanese typically product geographies. strides to make now launching time familiar products Finally, developing we that encouraged a a of than to realize continue Those market. we with are longer there a in remain the potential Japan, other in is lead the by new in
the time However, market is well effort. and large given the it worth opportunity,
about future and We remain are this encouraged are optimistic business. the of we making early the by strides
growth Our for drivers create next opportunities in develop the priority adjacent company. is to markets additional to
ways to beyond our us impossible, entire calls, As to to expand I for superior allografts, previous we business, tissue where the to amniotic substitute current this XenoGraft Notwithstanding our segments the it and/or evaluating our are if will is compete stated qualities strategy, skin placental be our market portfolio is open believe We a infrastructure. not difficult, of include of will market-driven drive complementary on synthetics. commercial which up us to this leverage allowing approach highly today.
are On move surface, effort inorganic direction. that excited much know And an an many financial I like sense. of this seems the to improved us see make profile, could in given where our area you
As have we cultural foremost, I to inorganic pathway have be to, growth excellent accretive. consideration. will them becoming clear careful would our any accelerate fit, have also which first target would applicable an strategic be and opportunities a and To potential plan. arise, clear, would for give
expense And finally, process is build management, discipline and last objective a around corporate rationalization improvement. our continuous to
the business in to has scales. focused pay about on a limited objective area, resources. getting continue institutionalizing this experience is on this as that from the the my best is leverage It will gaining more we this place expense goals building progress exceed in terms early put of our been to operating culture that dividends our measure really While return in mindset
progress During executing we strategic excellent made the against objectives. X quarter, these
that effects. desired the approach Our demonstrate results is having our
way business We for identify as will tremendous continue drivers value. against best to growth and performance we most as relevant execute our see sustained create long-term to the
past we to provide like preferred to Before on Friday. I the series repurchase few call turn this the stock in Doug, I'd over a comments executed
the First, could We Hayfin for like past for company. not thank of their partner. ask I a would to better continued and support
As our million. a Hayfin share position mandatory Ultimately, of effectively $X.X transition. of started criteria, resulted conversations might us meeting at how show stock buying and $X.XX of back with conversion an common to about orderly signs them began half we this total help manage converted for the we per in their
not A stock of company's repurchase priority in this typically for point my be evolution would capital. at the highest use
$X.XX. a shares good X% However, sense stopped the on this made executed since price was of and discount was a at it convert the at dividend opportunistic preferred and repurchased
at capitalize way as Given building any arise. the opportunities improved not we capacity, in borrowing our this which are ability much on impairing strategic rate do our and may that cash see we to
our Doug? the turn on call let Now to me results. Doug more financial for detail over
